

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

POLL RESULTS OF THE 2021 THIRD EXTRAORDINARY GENERAL MEETING

References are made to the notice of the extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) dated September 7, 2021. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE EGM

The Company has held the EGM at Meeting Room 201, 2nd Floor, Zylox-Tonbridge Industrial Park, No. 270 Shuyun Road, Cangqian Street, Yuhang District, Hangzhou, Zhejiang, the PRC on Thursday, September 23, 2021 at 2:00 p.m. The EGM has been held pursuant to the requirements of the PRC Company Law and the Articles of Association.

As at the date of the EGM, the total number of the Company’s Shares in issue was 332,401,001 Shares (including 201,881,003 Domestic Shares and 130,519,998 H Shares), which entitled the holders to attend the EGM and vote for or against on the resolutions (the “**Resolutions**”) proposed thereat. The number of Shareholders and proxies of Shareholders attending the EGM was 37. Shareholders and proxies of Shareholders who attended the EGM held a total of 315,205,547 voting Shares (including 201,880,933 Domestic Shares and 113,324,614 H Shares), representing approximately 94.83% of the total number of the Company’s voting Shares in issue.

To the best knowledge, information and belief of the Directors: (1) no Shareholders were required under the Listing Rules to abstain from voting on any of the Resolutions; (2) there were no Shares entitling the holders thereof to attend the EGM and abstain from voting in favor of any of the Resolutions under Rule 13.40 of the Listing Rules; and (3) no Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on any of the Resolutions. All Resolutions were put to vote by way of poll.

Tricor Investor Services Limited, the Company's H Share registrar, acted as the scrutineer for the vote-taking at the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of the Resolutions proposed at the EGM were as follows:

Ordinary Resolutions		Number of votes (%)	
		For	Against
1.	To consider and approve the proposed adoption of the H Share Award and Trust Scheme;	274,174,955 (86.98%)	41,030,592 (13.02%)
2.	To consider and approve the proposed authorization to the Board and/or the Delegatee to handle matters pertaining to the H Share Award and Trust Scheme; and	274,191,455 (86.99%)	41,014,092 (13.01%)

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the Resolutions numbered 1 and 2 above, these Resolutions were duly passed.

Special Resolution		Number of votes (%)	
		For	Against
3.	To consider and approve the proposed amendments to the Articles of Association.	315,205,547 (100%)	0 (0%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the Resolution numbered 3 above, the Resolution was duly passed.

For details of the Resolutions above, please refer to the Circular.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, September 23, 2021

As at the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.